[1] 国家感染性疾病临床医学研究中心. 肝内胆汁淤积症诊治专家共识(2021年版)[J]. 中华肝脏病杂志, 2022,30(2):137-146.
[2] 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 临床肝胆病杂志, 2022,38(1):62-69.
[3] Trauner M, Karpen S J, Dawson P A. Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease[J]. Hepatology, 2025,82(4):855-876.
[4] Boyer J L, Soroka C J. Bile formation and secretion:an update[J]. J Hepatol, 2021,75(1):190-201.
[5] Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury-what is the link?[J]. J Hepatol, 2017,67(3):619-631.
[6] Dawson P A, Karpen S J. Intestinal transport and metabolism of bile acids[J]. J Lipid Res, 2015,56(6):1085-1099.
[7] Ghallab A, Mandorfer M, Stirnimann G, et al. Enteronephrohepatic circulation of bile acids and therapeutic potential of systemic bile acid transporter inhibitors[J]. J Hepatol, 2025,83(5):1204-1217.
[8] Choudhuri S, Klaassen C D. Molecular regulation of bile acid homeostasis[J]. Drug Metab Dispos, 2022,50(4):425-455.
[9] Jansen P L, Ghallab A, Vartak N, et al. The ascending pathophysiology of cholestatic liver disease[J]. Hepatology, 2017,65(2):722-738.
[10] Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J]. J Hepatol, 2013,58(1):155-168.
[11] Gonzales E, Grosse B, Schuller B, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2:evidence for improvement of cholestasis with 4-phenylbutyrate[J]. Hepatology, 2015,62(2):558-566.
[12] Trauner M, Fuchs C D. Novel therapeutic targets for cholestatic and fatty liver disease[J]. Gut, 2022,71(1):194-209.
[13] Ziccardi I, Zorzi M, Pio D A. Beyond the pump:the evolving molecular landscape of intrahepatic cholestasis[J]. Diagnostics (Basel), 2026,16(5):726.
[14] Peverelle M, Campbell S, Peverelle J, et al. Review article:ileal bile acid transport (IBAT) inhibitors as an emerging treatment for cholestatic liver disease[J]. Aliment Pharmacol Ther, 2026.
[15] Sutton H, Sokol R J, Kamath B M. IBAT inhibitors in pediatric cholestatic liver diseases:transformation on the horizon?[J]. Hepatology, 2025,82(4):985-995.
[16] Wedemeyer H, Aleman S, Brunetto M, et al. Bulevirtide monotherapy in patients with chronic HDV:efficacy and safety results through week 96 from a phase Ⅲ randomized trial[J]. J Hepatol, 2024,81(4):621-629.
[17] Blank A, Eidam A, Haag M, et al. The NTCP-inhibitor myrcludex B:effects on bile acid disposition and tenofovir pharmacokinetics[J]. Clin Pharmacol Ther, 2018,103(2):341-348.
[18] Kowdley K V, Hirschfield G M, Coombs C, et al. COBALT:a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls[J]. Am J Gastroenterol, 2025,120(2):390-400.
[19] Panzitt K, Zollner G, Marschall H U, et al. Recent advances on FXR-targeting therapeutics[J]. Mol Cell Endocrinol, 2022,552:111678.
[20] Li X, Lu W, Kharitonenkov A, et al. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases[J]. J Intern Med, 2024,295(3):292-312.
[21] Gallucci G M, Hayes C M, Boyer J L, et al. PPAR-mediated bile acid glucuronidation:therapeutic targets for the treatment of cholestatic liver diseases[J]. Cells, 2024,13(15):1296.
[22] Bhushan S, Kowdley K V. Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease[J]. Curr Opin Gastroenterol, 2025,41(4):281-288.
[23] Beuers U, Banales J M, Karpen S J, et al. The history and future of bile acid therapies[J]. J Hepatol, 2025,83(5):1172-1188. |
